tors have been demonstrated in a rat syngeneic BMT model. More recently, an angiotensin II (AII) receptor antagonist has also been shown to be effective in the Angiotensin-converting enzyme (ACE) inhibitors can be used to prevent the development of radiation nephroprophylaxis of experimental BMT nephropathy.
To date, the experimental studies of prophylaxis of BMT pathy after BMT. In previous BMT nephropathy studies, ACE inhibitor therapy was started pre-BMT and nephropathy have used continuous treatment with ACE inhibitors or AII antagonists, with treatment starting before continued indefinitely. In preparation for clinical trials, studies were designed to determine whether effective the BMT conditioning regimen, and continuing indefinitely. [13] [14] [15] [16] [17] However, if these agents are to be used cliniprophylaxis could be achieved if ACE inhibitor therapy was started after engraftment, and to determine cally, it would be useful to know whether the start of drug therapy could be delayed until after engraftment. It would whether ACE inhibitors needed to be given indefinitely. The present studies in our rat syngeneic BMT model also be useful to know whether drug therapy would need to continue indefinitely. The answers to these questions showed that captopril therapy started 25 days post-BMT was as effective as therapy started prior to BMT.
could also shed light on the mechanism(s) underlying the beneficial effects of ACE inhibitor and AII antagonist therWhen ACE inhibitor therapy was discontinued 28 weeks after BMT, the protective effect was not lost if apy against radiation nephropathy. 18 If therapy is effective when started after TBI, then it would establish that the adequate control of azotemia had been maintained for 26 weeks. If adequate control of azotemia was not maineffect was not an example of classical chemical radioprotection. 19 If therapy can be safely discontinued, then it tained for 26 weeks, BMT nephropathy progressed rapidly when ACE inhibitor therapy ended, and slowly would imply that the treatment is fundamentally altering the expression of radiation injury rather than delaying it.
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when it was continued. Failure to control azotemia was a better predictor of renal failure than failure to control To answer these questions, two sets of studies were conducted in the rat syngeneic BMT model. In the first study, hypertension or proteinuria. Based on these preclinical studies, it would appear that ACE inhibitor therapy will animals started on captopril therapy at 25 days post-BMT were compared to animals that either started on captopril be effective in the prophylaxis of BMT nephropathy even if begun after engraftment, and that ACE inhibi-10 days pre-BMT, or given BMT without drug therapy. In the second study, animals were started on ACE inhibitor tors may not need to be given indefinitely. Keywords: kidney; radiation; bone marrow transplan-(captopril or enalapril) therapy prior to BMT, but the therapy was stopped in some animals 28 weeks after BMT. tation; ACE inhibitors
Materials and methods
Late-onset renal failure is an acknowledged complication of human bone marrow transplantation (BMT). [1] [2] [3] [4] [5] The synRat syngeneic bone marrow transplant model drome is characterized by azotemia, polyuria, proteinuria, and hypertension within 6-12 months after irradiation. 4, 5 It These studies were performed with 7-to 8-week-old male is clinically and histopathologically similar to acute radi-WAG/Rij/MCW rats that were bred and housed in a moderation nephritis; 6, 7 and is now presumed to be acute radiation ate security barrier. The animals were free of Mycoplasma nephritis.
4,5 A clinically and hispathologically equivalent pulmonis, Pseudomonas, and common rat viruses. No antisyndrome is seen in rats after either localized bilateral renal biotics, immunosuppressive drugs or known nephrotoxic irradiation [8] [9] [10] or after total body irradiation (TBI) plus agents were used in the animal facility. Animals were main-BMT. 9, [11] [12] [13] Classically, treatment of radiation nephropathy tained in the Animal Care Facilities of the Medical College has been held to be futile. However, over the past few years of Wisconsin, which are fully accredited by the American both the prophylaxis [13] [14] [15] [16] and treatment 8, 9 of renal radiation Association for Accreditation of Laboratory Animal Care. injury with angiotensin-converting enzyme (ACE) inhibiPrior to BMT, rats were given TBI with 15.5-20 Gy in six fractions over 3 days (4 h between the two daily fractions) at a dose rate of 0.48 Gy/min, using an orthovolt-Immediately after the end of the radiation course, animals and to normalize for animal size differences. 15 Tail-cuff systolic blood pressure (BP) was measured with a semireceived a syngeneic BMT. 11, 12 automatic machine. The average BP reading from 3 consecutive days was used for each time-point; animals were Antihypertensive therapy preconditioned to the BP apparatus.
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In the first study, 20 rats received no drug therapy (n = 6), or captopril at 500 mg/l in their drinking water starting 10 Statistical methods days before BMT (n = 9) or 25 days after BMT (n = 5). All of these animals were given 17 Gy TBI. An additional Physiologic data are shown as individual animal values or six animals received neither drugs nor TBI. All of these as geometric means with 95% confidence intervals, and animals were followed for 26 weeks; no animals were lost were compared by Mann-Whitney tests. Geometric means to follow-up during this interval.
were used because the physiological values in the groups In the second study, 104 rats received captopril at 500
showing abnormal renal function were better described by mg/l (n = 41) or enalapril at 50 mg/l (n = 33) in their drinka log-normal distribution than a normal distribution.
ing water, or no drug (n = 30) starting 10 days before TBI. Survival curves were determined by the Kaplan-Meier These animals were then given TBI at 15.5-20 Gy, foltechnique and compared using an extension of the lowed by syngeneic BMT. An additional 11 animals Kruskal-Wallis test. received neither drugs nor TBI. At 28 weeks after BMT, animals in each combination of drug and TBI dose were stratified by BUN, and half were removed from drug therResults apy (where the number of eligible animals was odd, the extra animal was assigned randomly). Irradiated animals
Delaying captopril therapy until after engraftment were followed for 53 weeks post-BMT or sacrificed when Continuous captopril therapy was highly effective in the moribund. When evaluated just before sacrifice, moribund prophylaxis of BMT nephropathy. At 26 weeks after 17 Gy animals were generally lethargic, pale, dehydrated, and had TBI plus BMT, animals not treated with captopril showed BUN Ͼ200 mg/dl; these animals were considered to have azotemia, proteinuria and elevated systolic blood pressure end-stage renal failure. Three animals were lost to follow-( Figure 1 ). In contrast, animals given continuous captopril up for reasons unrelated to the TBI: an enalapril-treated therapy were hypotensive, and had only slight azotemia and animal that was removed from drug therapy at 28 weeks proteinuria after the same interval ( Figure 1 ). At 26 weeks and which was sacrificed at 45 weeks post-BMT, and two after BMT, animals started on captopril therapy 25 days non-drug-treated animals that were sacrificed at 41 and 47
after BMT had renal function that was not significantly difweeks post-TBI. The animals on continuous ACE inhibitor ferent (P Ͼ 0.05 for all parameters) from that of the animals therapy in the second study were part of a larger study of on continuous captopril therapy ( Figure 1 ); and their renal the effects of continuous prophylaxis of BMT nephropathy function was dramatically and significantly (P Ͻ 0.003 for using various antihypertensive agents. 15 all parameters) better than that of animals given TBI without captopril therapy ( Figure 1 ). Thus, delaying the start of Analysis of renal function captopril therapy has no deleterious effects on the efficacy of the therapy. Physiologic data were collected at 6, 9, 13, 17, 26, 37 and 48 weeks after BMT. These included serum urea nitrogen ('BUN'), serum creatinine (selected time-points only),
Stopping captopril therapy at 28 weeks after BMT urine protein, urine creatinine, and blood pressure. BUN was assayed with a urease-nitroprusside colorimetric assay, Figure 2 shows serial measurements of the effect on renal function of cessation of captopril therapy at 28 weeks after serum creatinine with an enzymatic colorimetric assay, urine protein with a Coomassie blue colorimetric assay, and 17 Gy TBI plus BMT. After captopril therapy was stopped, control of blood pressure was gradually lost (Figure 2 , urine creatinine with a modified Jaffé reaction colorimetric assay. 15 center). The increase in blood pressure (vs animals on continuous therapy) was significant at both 37 (P = 0.04) and As a general rule, BUN is an imprecise indicator of glomerular filtration rate (GFR); 20 however, in this model, 48 weeks (P = 0.006). Despite the loss of control of blood pressure, adequate control of proteinuria continued (Figure the correlation of BUN and serum creatinine is very strong (r = 0.92 in the present study), and data from other studies 20 2, top) although there was a slight increase in UP/UC (vs animals on continuous therapy). This increase in UP/UC indicate that serum creatinine is an adequate marker of GFR. Because BUN is strongly correlated with serum creatwas not significant at either 37 (P Ͼ 0.20) or 48 weeks (P = 0.08). Control of azotemia (Figure 2 , center) continued inine and hence with GFR, and because BUN values were determined at all time-points, BUN rather than serum for the duration of the experiment despite the cessation of therapy (P Ͼ 0.20 at both 37 and 48 weeks). creatinine or creatinine clearance was used to assess renal function.
After 15 Gy TBI, the pattern is similar to that seen after 17 Gy TBI. If captopril therapy was stopped at 28 weeks Urine protein excretion was expressed as the ratio of urine protein to urine creatinine (UP/UC) in the same urine there was some loss of control of blood pressure at 37 weeks (Figure 3 ), and this loss became statistically signifisample; this was done to account for the known urinary concentration defect that occurs in renal radiation injury cant (P = 0.018) at 48 weeks. However, there was no sig- BUN was 40 mg/dl or less at 26 weeks, azotemia did not increase between 26 and 37 weeks, regardless of whether captopril therapy was continued. If BUN was greater than nificant loss of control of azotemia or proteinuria at either 37 or 48 weeks (all P Ͼ 0.20).
40 mg/dl at 26 weeks, azotemia increased dramatically between 26 and 37 weeks if treatment was stopped at 28 At higher TBI doses, interpretation of the physiological data was complicated by the loss of some animals from weeks; and even if captopril treatment was continued in these animals, azotemia still increased between 26 and 37 renal failure. Of the six animals that were given 18.5 and 20 Gy TBI and that remained on captopril therapy, all surweeks. At 48 weeks, the pattern was similar. Most animals whose BUN was below 40 mg/dl at 26 weeks showed little vived until the planned termination of the experiment at 53 weeks after TBI (Figure 4) . Of the seven animals that were or no further increase in azotemia between 26 and 48 weeks regardless of whether treatment continued after 28 weeks given 18.5 and 20 Gy TBI and removed from captopril therapy at 28 weeks, five developed renal failure between ( Figure 6 ). However, most animals whose BUN was above 40 mg/dl at 26 weeks developed renal failure by 48 weeks 31 and 41 weeks; the decrease in the time to development of renal failure was significant (P = 0.008). Given the loss if captopril therapy was stopped, and even the animals in this group that remained on captopril therapy showed of animals from renal failure, rigorous analysis of the physiological data is impossible. However, analysis of the increased azotemia between 26 and 48 weeks. survivors at 37 weeks ( Figure 3) shows evidence not only for loss of control of blood pressure (vs animals on continuStopping enalapril therapy at 28 weeks after BMT ous therapy), but also for loss of control of azotemia and proteinuria.
In this model, enalapril (at 50 mg/l) is less effective than captopril (at 500 mg/l) in the prophylaxis of BMT nephroIf analysis of the effects of stopping captopril therapy at 28 weeks is analyzed on the basis of the degree of azotemia pathy. 15 This can be seen in the current studies by the fact that azotemia and proteinuria, at a given TBI dose, were at 26 weeks, an interesting pattern is seen ( Figure 5) . If the higher at 26 weeks in the animals treated with enalapril ( Figure 7 ) than in the animals treated with captopril ( Figure  3 ). Figure 7 shows renal function at 37 weeks for animals whose enalapril therapy was stopped at 28 weeks vs those that remained on enalapril therapy for the duration of the experiment. The corresponding data on time to develop- In animals whose enalapril therapy was stopped 28 therapy, but the differences were not significant (0.14 Ͼ P (í, ).
Ͼ 0.05 for all comparisons) at either 37 (Figure 7 ) or 48 weeks. In animals whose enalapril therapy was stopped 28 weeks after 17 Gy TBI, blood pressure and azotemia were disappear when the data are analyzed on the basis of the degree of azotemia at 26 weeks ( Figure 5 ). As with captosignificantly higher (0.04 Ͼ P Ͼ 0.02 for all comparisons) than in animals on continuous enalapril therapy at both 37 pril, enalapril therapy can be stopped without a further increase in azotemia only if the BUN is 40 mg/dl or less weeks ( Figure 7 ) and 48 weeks. At TBI doses of 18.5 and 20 Gy, all seven animals that were removed from enalapril at 26 weeks. Thus the differences between the effects of stopping captopril (Figure 3 ) vs enalapril ( Figure 7 ) therapy therapy developed renal failure between 30 and 42 weeks, compared to just three of the seven animals that were on appear to be due to the lesser initial effectiveness of the enalapril therapy, a difference which may be due either to continuous therapy (Figure 4) . The decrease in time to development of renal failure was significant (P = 0.004).
an inherent difference between the ACE inhibitors or to the use of a suboptimal dose of enalapril. The differences between captopril and enalapril therapy N o c h a n g e b e t w e e n 2 6 a n d 4 8 w e e k s is the modern congener of classical radiation nephritis 6, 7 in have classically been held to be inevitable, progressive, and pril therapy was stopped at 28 weeks developed renal failure prior to 37 weeks, as did one animal that was on continuous enalapril therapy. The untreatable. 18, 21, 22 The progressive and untreatable nature of gray area shows the 95% confidence intervals for the physiological varilate tissue damage follows from the assumption that the ables at 26 weeks for these same animals.
injury is due to delayed mitotic cell death resulting from genetic injury that is produced and irrevocably fixed in place at the time of irradiation. The long latent period for approaches have been shown to modify significantly late normal tissue injury. 18 the expression of injury in the kidney is explained by assuming that the target cell population has a very long In the case of radiation nephropathy, the most effective approach to pharmacologic intervention appears to be the doubling time. Under this classical view, the only way to decrease the probability of injury is by limiting the radiuse of ACE inhibitors 8,9,13-16 or AII receptor antagonists.
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These agents, particularly the ACE inhibitor captopril, are ation dose 21, 22 or shielding the at-risk organs (eg renal shielding 23 ).
well-tolerated and approved by the US Food and Drug Administration for use in the treatment of hypertension and However, recent results from our lab and elsewhere have called the classical view of chronic radiation injury into diabetic nephropathy in humans. Clinical trials of captopril for the prophylaxis of late radiation injuries, including question. 18, 24 Pathophysiological data indicate that late radiation-induced tissue injury involves complex and dynamic BMT nephropathy, are being planned at several institutions, including the Medical College of Wisconsin. Several quesinteractions among parenchymal and vascular cells within a particular organ. Parenchymal and vascular cells are tions about the use of these agents needed to be resolved before clinical trials could be designed. One of the first viewed as active participants in the response to injury, rather than as passive observers dying as they attempt to questions that arose was whether captopril therapy needed to start prior to BMT. Although there was no biological divide. 18 This new model of chronic radiation injury offers a fundamentally new approach to improving the therapeutic reason to believe that delaying treatment until 3-4 weeks after BMT would decrease efficacy, it was important to ratio, because unlike the classical model, it allows for the possibility of pharmacological intervention after radiation demonstrate this in the experimental model. In the experiment shown in Figure 1 , we have unambiguously demonexposure. In fact, the experimental success of post-radiation therapeutic intervention is one of the prime reasons for the strated that a delay in the start of captopril therapy has little or no impact on the efficacy of the therapy. This experiment paradigm shift, as in recent years various pharmacologic group on captopril, as such radioprotection requires that the sulfhydryl compound be present at the time of irradiation. 19 The second issue was whether ACE inhibitor therapy
